van Rijswijk

Aug 27, 2024 | academic.oup.com | Amsterdam Reproduction |van Welie |van Rijswijk |van Hooff

Does hysterosalpingo-foam sonography (HyFoSy) prior to hysterosalpingography (HSG) or HSG prior to HyFoSy affect visible tubal patency when compared HSG or HyFoSy alone? Undergoing either HyFoSy or HSG prior to tubal patency testing by the alternative method does not demonstrate a significant difference in visible tubal patency when compared to HyFoSy or HSG alone.

May 6, 2024 | link.springer.com | van der Meer |van Rijswijk |van Erkel |van Duijn-de Vreugd

AbstractPercutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver.

Apr 10, 2024 | academic.oup.com | Amsterdam Reproduction |van Eekelen |van Welie |van Rijswijk

What are the costs and effects of tubal patency testing by hysterosalpingo-foam sonography (HyFoSy) compared to hysterosalpingography (HSG) in infertile women during the fertility work-up? During the fertility work-up, clinical management based on the test results of HyFoSy leads to slightly lower, though not statistically significant, live birth rates, at lower costs, compared to management based on HSG results.